drugset / Trial / NCT03920605
Optimized Treatment of Peginterferon Alfa 2a/2b in Treatment Experienced Patients With HBV Related Liver Fibrosis
RandomizedParallel-groupOpen-labelTreatment
Summary
Compared to nucleoside/nucleotide analogues, peginterferon alfa 2a/2b may has more therapeutic efficacy in hepatitis B surface antigen or e antigen seroconversion and anti-tumor occurrence in chronic hepatitis b patients. We design this study to investigate treatment of peginterferon alfa 2a/2b in anti-virus treatment experienced patients with HBV related liver fibrosis.
Timeline
- Start
- 2019-02-01
- Primary completion
- 2021-10-30
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | Subcutaneous |
| Comparator | Peginterferon alfa-2b | Protein / enzyme biologic | 80 ug | Subcutaneous |
| Comparator | Tenofovir disoproxil fumarate | Small molecule | 300 mg | Oral |